...
首页> 外文期刊>Journal of Veterinary Internal Medicine >Alternating Carboplatin and Doxorubicin as Adjunctive Chemotherapy to Amputation or Limb-Sparing Surgery in the Treatment of Appendicular Osteosarcoma in Dogs
【24h】

Alternating Carboplatin and Doxorubicin as Adjunctive Chemotherapy to Amputation or Limb-Sparing Surgery in the Treatment of Appendicular Osteosarcoma in Dogs

机译:交替使用卡铂和阿霉素作为截肢或保留肢体手术在犬阑尾骨肉瘤中的辅助化疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Thirty-two dogs with appendicular osteosarcoma treated by amputation or limb sparing had adjuvant chemotherapy of alternating doses of carboplatin (300 mg/m 2 IV) and doxorubicin (30 mg/m 2 IV) every 21 days for a total of 3 cycles. Efficacy, toxicity, and previously identified prognostic factors for osteosarcoma were evaluated. The median progression free survival was 227 days (range 180–274), and the median overall survival was 320 days (range 153–487). The 1-year survival rate was 48%, and the 2-year survival rate was 18%. Age, sex, surgical procedure, and alkaline phosphatase activity above the reference ranges were not prognostic for survival. There was minimal toxicity associated with the chemotherapy. This protocol could be useful for the adjuvant treatment of appendicular osteosarcoma of dogs.
机译:截肢或保留肢体治疗的32例阑尾骨肉瘤犬接受了交替剂量卡铂(300 mg / m 2 IV)和阿霉素(30 mg / m 2 IV)每21天共进行3个周期。评估了骨肉瘤的疗效,毒性和先前确定的预后因素。中位无进展生存期为227天(范围180-274),中位总生存期为320天(范围153-487)。 1年生存率为48%,2年生存率为18%。高于参考范围的年龄,性别,手术程序和碱性磷酸酶活性不能预后。与化学疗法相关的毒性最小。该方案可用于辅助治疗犬的阑尾骨肉瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号